S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   297.74 (-2.75%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   297.74 (-2.75%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   297.74 (-2.75%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
S&P 500   3,976.96 (-2.74%)
DOW   31,905.43 (-2.29%)
QQQ   297.74 (-2.75%)
AAPL   144.12 (-3.43%)
MSFT   258.75 (-3.02%)
FB   197.86 (-2.35%)
GOOGL   2,276.62 (-2.27%)
AMZN   2,193.04 (-4.95%)
TSLA   741.55 (-2.63%)
NVDA   176.70 (-2.79%)
BABA   89.96 (-2.21%)
NIO   16.50 (-0.78%)
AMD   100.98 (-1.45%)
CGC   5.82 (-1.19%)
MU   72.87 (-2.16%)
T   20.37 (-0.97%)
GE   75.81 (-0.77%)
F   13.03 (-3.70%)
DIS   105.95 (-2.48%)
AMC   13.54 (+4.96%)
PFE   50.80 (-1.05%)
PYPL   78.99 (-0.95%)
NFLX   184.63 (-3.11%)
LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Forecast, Price & News

GBX 55
+3.00 (+5.77%)
(As of 10/29/2020)
Add
Compare
Today's Range
50
56
50-Day Range
55
55
52-Week Range
28.60
115
Volume
70,791 shs
Average Volume
150,610 shs
Market Capitalization
£228.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive VRP News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

Verona Pharma plc (VRP.L) logo

About Verona Pharma plc (VRP.L)

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

Headlines

Verona Pharma Plc to Host Earnings Call
Verona Pharma Plc Share Chat
Verona Pharma plc : Update on AIM Delisting
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
22
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 17 per share
Book Value
GBX 18 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
£228.00 million
Optionable
Optionable

Company Calendar

Last Earnings
2/27/2020
Today
5/18/2022














Verona Pharma plc (VRP.L) (LON:VRP) Frequently Asked Questions

How were Verona Pharma plc (VRP.L)'s earnings last quarter?

Verona Pharma plc (VRP.L) (LON:VRP) released its earnings results on Thursday, February, 27th. The company reported ($30.30) earnings per share for the quarter, topping analysts' consensus estimates of ($30.80) by $0.50.
View Verona Pharma plc (VRP.L)'s earnings history
.

Who are Verona Pharma plc (VRP.L)'s key executives?
Verona Pharma plc (VRP.L)'s management team includes the following people:
  • Dr. Jan-Anders Karlsson, CEO & Exec. Director (Age 64)
  • Mr. Piers John Morgan, Chief Financial Officer (Age 53)
  • Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA, Gen. Counsel (Age 52)
  • Ms. Victoria Stewart, Director of Communications
  • Dr. Peter Spargo, Sr. VP of Chemistry Manufacturing & Controls (Age 57)
What other stocks do shareholders of Verona Pharma plc (VRP.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA), Fate Therapeutics (FATE), Pluristem Therapeutics (PSTI), AbbVie (ABBV), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Grifols (GRFS) and Innoviva (INVA).

What is Verona Pharma plc (VRP.L)'s stock symbol?

Verona Pharma plc (VRP.L) trades on the London Stock Exchange (LON) under the ticker symbol "VRP."

How do I buy shares of Verona Pharma plc (VRP.L)?

Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Verona Pharma plc (VRP.L)'s stock price today?

One share of VRP stock can currently be purchased for approximately GBX 55.

How much money does Verona Pharma plc (VRP.L) make?

Verona Pharma plc (VRP.L) has a market capitalization of £228.00 million.

How many employees does Verona Pharma plc (VRP.L) have?

Verona Pharma plc (VRP.L) employs 22 workers across the globe.

What is Verona Pharma plc (VRP.L)'s official website?

The official website for Verona Pharma plc (VRP.L) is www.veronapharma.com.

How can I contact Verona Pharma plc (VRP.L)?

Verona Pharma plc (VRP.L)'s mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.